Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Investigating how genetics affect response to oral semaglutide in prediabetes and obesity

Official title: Genetics of the Acute Response to Oral Semaglutide (GAROS)

Run by Medical University of Bialystok · NCT05340868 · Data updated 2026-11-12

This study is testing how genetics affect how well people with prediabetes and obesity respond to a three-month treatment with oral semaglutide.

More Obesity trials

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment1000 (estimated)
SponsorMedical University of Bialystok
Academic / other
Locations1 site (Bialystok, Podlaskie Voivodeship)
StatusRecruiting
StartedSeptember 1, 2022
Main results expectedDecember 31, 2025
Study endsDecember 31, 2025
Registry record updatedMarch 26, 2025
Trial IDNCT05340868 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-65 with a BMI over 30 or over 27 with prediabetes.

Probably not a fit

Patients with serious chronic diseases or those who have undergone bariatric surgery may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study explores the genetic factors influencing the response to a three-month treatment with oral semaglutide in individuals with prediabetes and obesity. Participants will undergo various assessments, including blood tests, glucose tolerance tests, and body composition analysis, to evaluate metabolic changes and hormonal responses. Additionally, genome-wide genotyping will be performed, and a subset of participants will have muscle and fat biopsies, along with MRI assessments of fat content in the liver, muscle, and pancreas. The goal is to understand how genetic variations impact treatment outcomes.

Why it matters

Potential benefit: If successful, this study could lead to personalized treatment strategies for prediabetes and obesity based on genetic profiles.

How similar studies have gone: While pharmacogenetic studies are common, this specific approach to semaglutide response in prediabetes is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Informed consent was given before any study-related action on the subject.
* Age: 18-65 years old
* Body mass index (BMI) \>30 kg/m2 or \>27 kg/m2 when accompanied by prediabetes, diagnosed according to the criteria of the American Diabetes Association

Exclusion Criteria:

* Patients diagnosed with a serious chronic disease, including:

  * Ischemic heart disease
  * Heart failure (NYHA class III-IV)
  * Severe renal insufficiency (eGFR \<30 ml/min)
  * Severe liver diseases
  * Inflammatory bowel disease
  * Diabetic gastroparesis
  * Cancer - currently or in the last five years prior to screening
  * Chronic obstructive pulmonary disease
  * History of mental illness, major depression or other severe mental disorders
* Use of any medications with clinically-proven significant weight gain or loss effects
* History of undergoing bariatric surgery or other surgery involving the stomach that could affect the absorption of the study drug (according to the investigator's opinion)
* History of idiopathic acute pancreatitis
* A family or personal history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid cancer
* For women - pregnancy, breastfeeding or planning pregnancy.
* Women of childbearing age who are not using highly effective methods of contraception
* Known or suspected hypersensitivity to the test product

Where it's running

  • Clinical Research Centre, Medical University of Bialystok
    Bialystok, Podlaskie Voivodeship, Poland
    Recruiting

Study contacts

  • Principal investigator: Lukasz Szczerbinski, MD, PhD — Clinical Research Centre, Medical University of Bialystok
  • Study coordinator: Lukasz Szczerbinski, MD, PhD
  • Email: lukasz.szczerbinski@umb.edu.pl
  • Phone: +48858318150

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.